|  |  |  |
| --- | --- | --- |
| Sarah Fitt  | Pharmac Chief Executive | sarah.fitt@pharmac.govt.nz |
| Lisa Williams | Pharmac Director of Operations | lisa.williams@pharmac.govt.nz |
| Dr David Hughes  | Pharmac Chief Medical Officer | david.hughes@pharmac.govt.nz |
| Trevor Simpson  | Pharmac Chief Advisor, Māori | trevor.simpson@pharmac.govt.nz |
| Consumer Advisory Committee  | Pharmac Consumer Advisory Committee  | cac@pharmac.govt.nz |
| Hon Steve Maharey  | Pharmac Chair | steve.maharey@pharmac.govt.nz |
| Dr Claudia Wyss  | Pharmac Deputy Chair | claudia.wyss@pharmac.govt.nz |

Please copy and paste the following into an email and send it to as many of those above as you can.

Dear (Name)

My name is (name) and I have multiple myeloma **OR** /my (relationship to you, eg mum, husband) has multiple myeloma.

I understand that Pharmac will soon be considering funding daratumumab and I ask you, please, fund it.

There is a desperate need for better myeloma treatments in New Zealand. Thalidomide is currently the second and last line of treatment for those who have had a stem cell transplant. We need better, more modern treatments that can allow patients to live productive lives.

When you consider funding daratumumab, please remember that no new myeloma treatments have been funded for eight years so daratumumab is needed urgently. Myeloma patients deserve to have access to modern treatments.

While daratumumab is what you are considering now, we need many more treatments for myeloma. It was concerning to find out that Australia now has five more funded treatments for what can be a chronic disease when you have access to better treatments. Please remember the wider need for better myeloma treatments in future decisions.

Regards

(Name)